{ "topic_representations": { "-1": [ [ "Immunotherapy and Tumor Microenvironment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "0": [ [ "Cancer Survival and Healthcare Access", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "1": [ [ "\nChimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "2": [ [ "Glioblastoma research and treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "3": [ [ "\"3D Organoid Culture in Cancer Research\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "4": [ [ "Kras G12C Inhibitors and Resistance", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "5": [ [ "\nAcute Myeloid Leukemia Treatment and Drug Screening", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "6": [ [ "Spatial imaging of tissue microenvironments", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "7": [ [ "Prostate cancer and AR degradation", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "8": [ [ "Parp Inhibition and DNA Damage Repair", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "9": [ [ "Pancreatic Ductal Adenocarcinoma (PDAC) Microenvironment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "10": [ [ "Topoisomerase 1 Inhibitors Adc Development", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "11": [ [ "Hepatocellular Carcinoma Treatment Research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "12": [ [ "EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "13": [ [ "Glutamine Metabolism in Cervical Cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "14": [ [ "\n\"Nanoparticle-based cancer treatment\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "15": [ [ "Bone metastasis in breast cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "16": [ [ "Microbiome and Immunotherapy in Cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "17": [ [ "Triple Negative Breast Cancer (TNBC)", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "18": [ [ "\nOral Squamous Cell Carcinoma (OSCC) Research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "19": [ [ "Melanoma therapy and Braf inhibitors", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "20": [ [ "Immunomodulation of Glioblastoma with Sting Agonism", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "21": [ [ "\n\"Anticancer mechanisms of natural compounds\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "22": [ [ "Renal Cell Carcinoma Subtypes", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "23": [ [ "\n\"Liquid Biopsy Using Urine and Plasma Samples\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "24": [ [ "Award ceremony speech draft", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "25": [ [ "\nTCR-engineered therapy for cancer treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "26": [ [ "T-cell engagers for cancer treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "27": [ [ "Colorectal cancer research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "28": [ [ "Obesity and breast cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "29": [ [ "Ferroptosis in cancer treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "30": [ [ "Trop2-targeted ADCs for cancer treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "31": [ [ "Hippo pathway inhibitors", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "32": [ [ "Immunotherapy in mice", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "33": [ [ "\nClinical trials of immunotherapies", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "34": [ [ "Immunity checkpoint inhibitors and resistance", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "35": [ [ "Pancreatic cancer research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "36": [ [ "Drug combination screening", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "37": [ [ "\nPancreatic Cancer Research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "38": [ [ "Her2 expression in solid tumors", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "39": [ [ "Smoking-induced lung cancer research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "40": [ [ "\n\"Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "41": [ [ "Prostate cancer research and treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "42": [ [ "Cyclin-dependent kinase 2 inhibition in cancer therapy", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "43": [ [ "\n\"Methylation Detection from Cell-Free DNA\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "44": [ [ "Medulloblastoma research and treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "45": [ [ "Single-cell RNA sequencing and chromatin accessibility analysis", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "46": [ [ "\n\"MTA-PRMT5 Inhibitors for Cancer Treatment\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "47": [ [ "Anti-PD-1 therapy in NSCLC", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "48": [ [ "Immunomodulation with IL-18 and PD-1 antagonists", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "49": [ [ "RMS and Pax3-Foxo1 Fusion Protein Research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "50": [ [ "\n\"Chromatin organization and gene regulation in breast cancer\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "51": [ [ "Multi-Cancer Early Detection Tests", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "52": [ [ "\nMitochondrial dysfunction in cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "53": [ [ "Cholangiocarcinoma research and treatments", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "54": [ [ "Immune cell analysis with cytof", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "55": [ [ "\n\"Circulating Tumor DNA Monitoring in Cancer Treatment\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "56": [ [ "Cellular thermal shift assay (CTSA) for target engagement", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "57": [ [ "\"FFPE Library Prep Methods\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "58": [ [ "\n\"Lung Cancer Classification and Targeting\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "59": [ [ "Immunotherapy biomarkers in cancer patients", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "60": [ [ "Colorectal cancer genomics and mutations", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "61": [ [ "Epithelial-mesenchymal transition and plasticity in cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "62": [ [ "Electric fields for cancer treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "63": [ [ "Cancer-associated fibroblasts in tumor microenvironment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "64": [ [ "\nProstate cancer research and diagnosis", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "65": [ [ "\nAcquired drug resistance and persister cells", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "66": [ [ "\n\"EAC and Barrett's Esophagus Research\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "67": [ [ "\n\"Lung Cancer Research\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "68": [ [ "\n\"Cachexia and Muscle Wasting in Cancer Patients\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "69": [ [ "Cloud-based data governance for cancer research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "70": [ [ "Ewing Sarcoma Research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "71": [ [ "\n\"Immunotherapy targeting Tregs\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "72": [ [ "\nNano-immunotherapy for cancer treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "73": [ [ "\n\"Trial of T-1101 and T-1201 in Cancer Treatment\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "74": [ [ "Radiation and Immunity in Cancer Treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "75": [ [ "Immunotherapy and Neoantigens", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "76": [ [ "Aging and immune system in cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "77": [ [ "\nProgesterone and breast cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "78": [ [ "\n\"Gut Microbiome in CRC Patients\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "79": [ [ "Hematopoiesis and Clonal Variants", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "80": [ [ "\n\"Kinase Inhibition and Targeting\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "81": [ [ "Paralog selective degraders for cancer therapy", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "82": [ [ "\n\"Immunotherapy for Melanoma\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "83": [ [ "Genome-scale measurements for tumor normal benchmark", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "84": [ [ "Immunotherapy for bladder cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "85": [ [ "Hematopoietic Progenitor Kinase 1 Inhibition", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "86": [ [ "\nVariants of Uncertain Significance (VUS)", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "87": [ [ "\n\"Colorectal cancer detection\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "88": [ [ "Claudin18 Targeted Therapy", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "89": [ [ "\n\"AI-based tumor purity analysis\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "90": [ [ "Bispecific antibody development for cancer treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "91": [ [ "\n\"Genomic Variant Detection\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "92": [ [ "Prostate cancer in African men", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "93": [ [ "\n\"Microsatellite Instability and WRN Helicase Inhibition\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "94": [ [ "Immunosuppression and antibody-enhancing drugs", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "95": [ [ "\n\"Immune Checkpoint Inhibitor Adverse Events\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "96": [ [ "Neuronal influence on cancer growth", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "97": [ [ "\"Uveal Melanoma and Selenoproteome Expression\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "98": [ [ "HBV and HCC Treatment Studies", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "99": [ [ "\nBtk Inhibitors and Resistance Mechanisms", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "100": [ [ "\n\"Tertiary Lymphoid Structures in Cancer Prognosis\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "101": [ [ "Extrachromosomal DNA in cancer research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "102": [ [ "Smarca2/4 degraders for cancer treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "103": [ [ "\n\"Epigenetic Regulators and Cancer Treatment\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "104": [ [ "Bispecific anti-egfr/cmet adc", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "105": [ [ "Transposable elements and cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "106": [ [ "\n\"ER Degradation Therapy for Breast Cancer\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "107": [ [ "Macrophage-based therapies in cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "108": [ [ "\n\"Genomic Alterations in NSCLC\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "109": [ [ "Bladder Cancer Diagnosis and Monitoring", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "110": [ [ "\n\"Genomic profiling for cancer diagnosis\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "111": [ [ "TCR Repertoire in Cancer Patients", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "112": [ [ "Kras Vaccine Development", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "113": [ [ "\n\"G-quadruplex Targeting Compound in Pancreatic Cancer Treatment\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "114": [ [ "\nClinical efficacy of dual Her2 inhibition in metastatic colorectal cancer (MCRC)", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "115": [ [ "Liquid biopsy for glioma monitoring", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "116": [ [ "\nMismatch repair and immune checkpoint inhibitors", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "117": [ [ "\n\"Immunomodulatory effects of mushroom consumption in prostate cancer.\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "118": [ [ "Nectin-4 targeted ADCs", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "119": [ [ "Single-cell gene expression technologies", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "120": [ [ "\nHead and neck cancer subtyping", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "121": [ [ "Cancer Vaccine Development", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "122": [ [ "Proteomic analysis of cancer tissues", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "123": [ [ "\n\"Lymphoma Prognostics and Treatment Strategies\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "124": [ [ "\n\"Chemotherapy Resistance Mechanisms in Colorectal Cancer\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "125": [ [ "Cancer-associated fibroblasts research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "126": [ [ "\nCondensate-based drug discovery", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "127": [ [ "\n\"Metabolism and Cancer Treatment\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "128": [ [ "Stat3 degraders for cancer therapy", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "129": [ [ "Melanoma research and embryonic development", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "130": [ [ "\n\"Ovarian Cancer Biomarkers\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "131": [ [ "\nLncRNA and Promoter Regulation in Cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "132": [ [ "Immunotherapy in cancer treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "133": [ [ "\n\"Ferroptosis in Cancer Cells\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "134": [ [ "\n\"Cdk4 Inhibitors and Breast Cancer Resistance\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "135": [ [ "Radiation therapy and DNA damage response inhibitors", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "136": [ [ "Liquid biopsy for cancer diagnosis and treatment response.", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "137": [ [ "Brain Metastasis Survival Analysis", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "138": [ [ "\nMolecular Biomarkers in Breast Cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "139": [ [ "\nP53 and RPL22 in Cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "140": [ [ "Colorectal cancer research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "141": [ [ "\n\"Tumor Suppression Mechanisms\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "142": [ [ "Radiation-induced salivary gland damage and regeneration", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "143": [ [ "\n\"Adenosine Signaling and Immunotherapy\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "144": [ [ "Sarcopenia and ICI in NSCLC", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "145": [ [ "Ethnic disparities in lymphoma survival", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "146": [ [ "Liquid biopsy for lung cancer screening", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "147": [ [ "\n\"KDM6A Loss in Urothelial Carcinomas\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "148": [ [ "Immuno-oncology screens with CRISPR and RNA-seq", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "149": [ [ "P53 Restoration Therapy", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "150": [ [ "Immunometabolic targeting in cancer immunotherapy", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "151": [ [ "\n\"Breast cancer recurrence and gene regulation\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "152": [ [ "Head and neck squamous cell carcinoma (HNSCC) research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "153": [ [ "\n\"HCC Immune Cells Study\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "154": [ [ "\n\"Pd-L1 IHC Scoring Methods\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "155": [ [ "Ovarian Cancer Glycosylation and Metastasis", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "156": [ [ "\n\"Ubiquitin-Proteasome System in Cancer Treatment\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "157": [ [ "\nClinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "158": [ [ "Immunotherapy in Non-Small Cell Lung Cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "159": [ [ "Anlotinib + Chemo for Advanced Escc Treatment", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "160": [ [ "\n\"Myc Targeting Technologies\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "161": [ [ "Neuroblastoma Epigenetics Study", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "162": [ [ "\n\"Metastasis and Genetic Alterations\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "163": [ [ "T Cell Exhaustion and Stemness Programs", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "164": [ [ "\nProstate cancer research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "165": [ [ "\n\"Lung Cancer Microenvironment Analysis\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "166": [ [ "\n\"Pi3k/Akt Inhibitors in Breast Cancer\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "167": [ [ "\n\"Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis\"", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "168": [ [ "Extracellular Vesicle Research in Ovarian Cancer", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "169": [ [ "Colorectal Cancer Secondary Malignancies in Young Adults", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "170": [ [ "Molecular Glues Targeting Cancer-Specific E3 Ligases", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "171": [ [ "Epigenetics and Cancer Research", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "172": [ [ "Immunogenic neoantigens and NMD inhibition in cancer immunotherapy", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ], "173": [ [ "Click Activated Prodrugs Against Cancer Platform", 1 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ], [ "", 0 ] ] }, "topics": [ 5, -1, -1, -1, -1, -1, 33, -1, 33, -1, 7, 41, -1, -1, 113, 0, 57, 1, -1, 24, 21, -1, 171, -1, -1, -1, 9, 1, -1, 20, -1, -1, -1, 58, 98, -1, -1, -1, -1, -1, -1, 3, -1, 0, -1, -1, 157, 8, 17, 1, 1, -1, 50, 7, 11, -1, 24, 107, 15, 20, 84, 41, 5, 98, -1, -1, 59, -1, 0, -1, -1, -1, 38, -1, 134, -1, -1, -1, 0, -1, 24, 0, -1, -1, 0, -1, -1, -1, -1, 133, -1, 8, 1, 82, 3, -1, 18, -1, 111, 24, 0, 2, -1, 24, -1, 64, -1, -1, 0, 124, 14, 107, -1, 153, -1, 35, -1, 0, -1, 24, -1, -1, 5, 2, 159, 56, 51, -1, -1, -1, 155, 59, 131, 29, -1, -1, -1, -1, -1, -1, -1, -1, -1, 24, -1, -1, 68, -1, 23, 4, -1, -1, -1, -1, 24, -1, 6, -1, 2, 171, 40, -1, 106, -1, -1, 18, 0, -1, -1, -1, 157, -1, 27, 7, -1, -1, -1, 0, -1, -1, -1, -1, -1, 45, -1, 11, 11, 0, -1, 24, 11, -1, -1, 63, -1, 73, -1, 24, 156, -1, 73, -1, 137, 2, -1, -1, -1, 9, 158, 126, -1, 2, 137, 2, 24, -1, 21, -1, 104, 17, 117, -1, 24, 24, 8, -1, 99, 1, -1, 0, -1, -1, -1, 2, 24, -1, -1, 24, 24, -1, -1, 24, 55, -1, 24, 36, 34, -1, 24, 20, 24, -1, -1, 1, -1, 8, 24, 0, 24, -1, 24, -1, -1, 0, 0, -1, -1, -1, 149, -1, 21, 0, 50, 1, -1, -1, 40, 67, 19, 1, 66, 159, -1, -1, 53, 60, 29, -1, 6, 11, 10, 10, -1, 71, -1, -1, 136, -1, 61, -1, 86, -1, 102, 87, -1, -1, -1, 4, -1, 13, -1, -1, -1, 29, 158, 71, 7, 21, 42, -1, -1, 3, 26, 0, -1, 102, 0, 0, -1, 22, 6, 0, -1, 137, 108, -1, -1, 35, -1, 13, 151, -1, -1, 4, 6, 6, -1, 140, -1, 42, 85, -1, 15, -1, 46, -1, -1, 8, 16, 89, 89, -1, -1, 14, -1, 67, 19, 21, 11, 123, -1, -1, 103, -1, 5, -1, 0, 1, 168, 138, -1, 31, -1, 61, -1, -1, 1, -1, 6, -1, 15, -1, 14, 2, -1, 2, 30, 3, 3, -1, 7, -1, 2, 14, 10, 87, 68, -1, -1, 18, 11, 11, 16, 3, 13, 13, -1, 2, 10, -1, -1, -1, -1, -1, -1, -1, -1, 54, 27, -1, -1, 88, 0, 42, 2, -1, -1, 0, -1, -1, -1, -1, 83, -1, -1, 35, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 125, 103, 29, 72, 38, -1, 38, -1, 65, -1, 4, 99, -1, -1, -1, 88, -1, 19, 4, 166, -1, 71, 1, -1, 80, -1, -1, 0, 8, 8, 42, 5, -1, -1, 5, 9, -1, -1, 11, 71, 4, -1, -1, 6, -1, 52, -1, 15, 15, 4, -1, 45, -1, 2, -1, 68, -1, -1, 0, -1, 61, -1, -1, 128, -1, 18, 25, -1, -1, 169, 60, 27, -1, -1, 75, 116, 8, 7, 18, -1, -1, -1, 7, -1, -1, 27, 37, 52, -1, -1, 78, -1, 14, -1, 39, -1, 0, 45, -1, -1, -1, 24, 24, -1, 159, -1, -1, -1, 27, 137, 14, -1, 25, 30, 24, 24, -1, 136, -1, 33, 11, -1, 13, -1, 24, -1, 24, 24, 8, -1, -1, -1, -1, 24, -1, -1, 48, 24, -1, 31, 24, 33, 24, 24, 6, 47, 2, 58, 33, -1, 121, 159, -1, 1, 25, -1, -1, 73, 24, -1, 33, 88, -1, -1, -1, -1, -1, -1, 33, -1, -1, 3, 2, -1, 59, -1, 50, -1, 16, -1, 47, 47, 47, -1, -1, -1, 84, 47, 121, -1, 33, -1, -1, 4, -1, 73, 73, -1, -1, 4, -1, -1, -1, 132, -1, -1, -1, -1, 2, -1, -1, -1, 98, -1, -1, 21, -1, -1, 136, -1, 3, 12, 0, 4, -1, 136, 115, -1, 138, 9, -1, -1, -1, 6, 6, 6, 18, 1, -1, -1, 10, 15, -1, 93, -1, -1, 25, -1, -1, 34, 10, -1, -1, -1, 2, -1, -1, -1, 138, -1, 11, -1, -1, 0, 0, 0, 0, 2, 13, -1, -1, 3, -1, 6, -1, -1, -1, 63, 28, 73, 10, -1, 2, 83, -1, 14, 3, -1, -1, 75, 11, 1, 25, 0, 141, 65, -1, 21, -1, -1, -1, -1, -1, 102, -1, -1, -1, 15, -1, 6, 79, -1, -1, -1, -1, 54, -1, 10, -1, 74, 0, -1, 2, 94, 60, -1, -1, 32, 76, 2, 1, -1, -1, -1, 62, 62, 65, -1, 101, 17, -1, 4, 8, 3, 36, -1, 21, 13, 21, 3, 60, -1, -1, 47, -1, 133, 6, 166, 1, 69, -1, 0, -1, 75, 36, 91, 28, 20, -1, -1, -1, 58, 95, 54, 54, 1, -1, -1, 51, -1, -1, 5, -1, 57, 10, 74, 21, -1, -1, -1, 24, 63, 32, 3, 3, 32, -1, 1, -1, -1, -1, 3, 153, 71, 13, 4, -1, -1, -1, -1, 75, 80, 0, 37, 2, -1, -1, 0, 2, -1, -1, -1, 6, 5, -1, 35, 54, -1, -1, 0, -1, -1, -1, -1, 21, 54, -1, -1, 4, 10, 3, 36, 15, 5, 160, 157, 7, -1, -1, 9, 47, -1, 2, 29, 2, 1, 0, 0, 34, -1, 0, -1, 0, 2, -1, 37, -1, -1, 23, 52, -1, 12, 0, 19, 9, 139, 13, -1, 76, -1, 0, 50, -1, -1, 122, 7, 7, -1, 4, 150, 1, -1, 50, 61, 135, -1, -1, -1, -1, 56, 16, 6, 5, -1, 97, -1, 105, 0, 39, 0, 129, 45, 37, 1, -1, 1, 1, 25, 75, 83, 5, -1, -1, 13, -1, -1, 27, -1, 5, 101, -1, -1, -1, -1, 107, 1, 24, 50, 20, -1, 0, -1, 59, -1, 96, 96, -1, -1, -1, 0, 39, 0, 42, 52, 28, -1, -1, -1, 86, 0, 0, 130, -1, -1, 140, -1, 39, 69, 4, 39, 86, -1, -1, 83, -1, -1, 6, 75, -1, 9, -1, 101, 30, -1, -1, 51, -1, 4, 4, 4, -1, -1, -1, 12, 38, 59, 55, 54, 158, 4, -1, 0, 0, 0, 0, 0, 0, -1, 141, 50, -1, 7, 7, 28, 2, -1, -1, 70, -1, 7, 149, -1, -1, 7, 7, -1, -1, -1, -1, 12, 13, -1, -1, 65, 12, 5, 36, -1, 14, -1, 5, 15, -1, 10, 118, -1, 10, -1, -1, -1, 58, -1, 51, -1, 2, -1, -1, 139, 2, -1, -1, -1, -1, 139, -1, 70, -1, 5, 15, 79, -1, -1, -1, -1, 102, 128, -1, -1, -1, 26, 40, -1, 107, 76, -1, -1, -1, -1, -1, -1, -1, -1, -1, 167, -1, 55, 55, 55, -1, 13, 27, 20, -1, 13, 13, 68, -1, -1, -1, 9, -1, 7, -1, 16, 16, 16, 16, 16, -1, -1, 60, 0, -1, -1, 0, -1, 77, -1, -1, -1, -1, 106, 106, 51, 51, -1, 51, -1, 51, 51, -1, -1, 4, 2, -1, 44, -1, 76, -1, -1, -1, -1, -1, 20, -1, 129, 22, 4, -1, 36, 67, -1, 7, -1, 11, 12, -1, -1, 31, -1, 4, 93, 5, 49, 36, 170, -1, -1, -1, 40, 4, -1, -1, 37, -1, 9, -1, -1, 8, -1, 18, 8, -1, -1, -1, 9, 20, 9, -1, -1, 26, -1, -1, -1, 88, -1, -1, 76, -1, -1, -1, -1, -1, 20, -1, 4, -1, 7, -1, 42, 4, 10, 14, 19, 93, 42, 0, 0, -1, 32, -1, -1, -1, -1, 1, -1, 85, 25, -1, -1, 77, 3, -1, -1, -1, 119, -1, -1, 34, 28, 77, 28, 9, 119, -1, 172, -1, -1, -1, -1, -1, 25, 25, -1, 25, 107, 25, 112, 25, 1, -1, 25, 1, 25, 25, -1, 25, 150, 150, 3, 25, 111, 25, -1, 1, 25, -1, -1, 1, 1, 1, 1, 1, -1, -1, -1, 1, -1, 20, 1, -1, 2, 5, 1, 1, 1, 1, -1, -1, 1, -1, 1, -1, -1, 25, 1, 53, 9, -1, -1, -1, -1, -1, 84, -1, -1, 74, -1, 62, 62, -1, 2, -1, -1, -1, 1, -1, -1, -1, -1, 34, -1, -1, 34, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, -1, -1, 0, -1, 69, -1, -1, 0, 0, -1, 0, 0, 0, 110, 0, 0, -1, 65, 7, -1, -1, 13, -1, -1, -1, -1, 155, 133, 14, 65, -1, 9, 7, -1, 155, -1, -1, 162, -1, 11, -1, -1, -1, 3, 15, 3, 4, -1, -1, 19, 27, -1, -1, 1, -1, -1, -1, 3, 5, -1, 3, 15, 32, -1, -1, 2, 68, -1, -1, 20, -1, 3, 3, 3, 3, -1, 164, -1, 15, 168, 2, 3, -1, 3, -1, 15, 32, 1, -1, 3, -1, -1, 3, -1, 96, -1, -1, 3, 3, 3, 3, 3, -1, 99, 106, 3, 53, -1, -1, 3, 3, 9, 3, 2, -1, 3, 2, 4, -1, 3, 53, -1, 3, -1, -1, -1, -1, 2, 6, 63, -1, -1, 100, 6, 6, -1, 165, -1, -1, -1, -1, -1, 18, -1, 2, 6, -1, 6, 6, -1, -1, 63, 2, 6, 5, -1, 140, 61, 142, 7, 18, 50, 2, 66, -1, -1, -1, -1, -1, 5, -1, -1, 27, 3, 3, 3, -1, 3, 3, 3, 3, 3, -1, -1, 3, 3, 3, 3, 3, 3, 3, 3, 46, 3, 3, 3, -1, -1, -1, -1, 67, 9, -1, 4, 74, 9, 9, 9, 9, 9, -1, 9, -1, -1, 125, 9, 11, 9, 9, 9, -1, 9, 125, 9, -1, 9, 68, 9, 9, -1, 9, 0, 0, 44, 44, -1, -1, -1, 161, -1, 44, 70, -1, -1, -1, 45, -1, 49, -1, -1, 44, 161, 49, 4, 28, 5, 96, -1, -1, 63, -1, -1, 5, -1, -1, -1, 28, -1, -1, -1, 76, 2, 6, 63, -1, 28, 27, 117, 19, 5, 63, 64, -1, -1, -1, -1, -1, -1, -1, -1, 83, -1, -1, 6, -1, 45, 2, 38, 61, -1, -1, -1, 22, 101, -1, 52, -1, 96, -1, -1, 15, -1, -1, -1, -1, 39, -1, 63, -1, -1, -1, 15, -1, -1, -1, -1, -1, -1, -1, 17, -1, -1, 15, -1, -1, -1, -1, 13, 2, -1, -1, 18, -1, 9, 15, 74, -1, -1, 152, -1, -1, -1, 15, -1, -1, 141, -1, -1, -1, -1, 172, 9, 3, -1, 3, -1, 9, -1, 3, 63, -1, 9, -1, -1, -1, -1, -1, -1, -1, 3, -1, 124, 3, 124, 44, -1, 18, 111, 162, -1, 101, -1, -1, 60, -1, -1, -1, 22, 130, -1, 147, 11, 11, 3, -1, 3, 17, 8, -1, 9, -1, -1, 3, -1, -1, -1, -1, -1, 2, -1, 2, 6, 6, -1, -1, 3, -1, 72, -1, -1, 7, -1, -1, -1, -1, 27, 40, 2, -1, -1, 5, 5, 31, 50, 5, 7, 2, 18, -1, -1, 5, -1, 68, -1, 13, -1, 18, -1, -1, -1, -1, 13, -1, -1, -1, -1, -1, -1, 168, 28, -1, -1, 12, -1, -1, -1, 44, 0, 7, -1, 11, -1, -1, 27, -1, 52, -1, 105, -1, 5, 52, 50, -1, 126, -1, -1, -1, -1, 37, 63, 7, -1, -1, 107, -1, -1, 35, -1, -1, -1, -1, -1, 2, -1, -1, 1, -1, 40, -1, 2, -1, -1, 15, -1, -1, -1, 39, 50, 67, 65, 22, -1, 22, 67, -1, 7, 7, 7, 97, -1, -1, -1, 6, -1, 36, 7, 67, -1, 119, 57, 45, -1, -1, -1, 5, -1, 57, -1, 23, 57, -1, 57, -1, 5, -1, 57, -1, -1, -1, 45, -1, 91, 5, 23, 57, 119, -1, -1, 83, -1, -1, -1, 3, -1, -1, 91, 110, -1, -1, 110, -1, 57, -1, 165, -1, -1, 148, -1, -1, 0, 4, -1, 17, -1, 35, -1, -1, 11, -1, -1, 29, -1, 4, 4, 4, 31, -1, 19, -1, 31, -1, 31, 4, 4, -1, -1, 4, 11, 4, -1, -1, 44, 4, 4, -1, 80, -1, 7, -1, 7, -1, 8, -1, 16, 8, -1, -1, 93, -1, 2, -1, 50, -1, 86, 8, -1, 30, 149, 19, 4, 103, 11, 9, 18, -1, 27, 17, -1, 18, 13, 17, 155, -1, 67, -1, -1, -1, -1, -1, -1, -1, -1, 29, 29, 29, 29, -1, 2, 29, 5, 133, 41, -1, 15, -1, -1, 2, -1, 142, -1, -1, -1, -1, -1, -1, -1, -1, -1, 126, 76, -1, -1, -1, -1, -1, 9, 97, -1, 0, 2, -1, 18, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 101, -1, -1, -1, -1, -1, 120, -1, -1, -1, 22, 22, -1, -1, -1, 5, -1, -1, 27, 81, -1, 11, -1, 50, -1, 37, -1, -1, -1, 5, 97, -1, -1, -1, -1, 22, -1, 131, -1, 39, 43, -1, -1, -1, 92, 43, 43, 0, 5, -1, -1, -1, -1, -1, 169, -1, 43, -1, -1, 43, -1, 43, 43, -1, -1, 92, -1, 43, -1, -1, -1, -1, -1, 5, 11, 5, 49, 57, -1, -1, -1, 27, -1, -1, -1, 50, -1, 139, -1, -1, 129, 7, -1, -1, 7, 101, 13, -1, -1, 13, -1, -1, -1, -1, 13, -1, 35, -1, 68, -1, 29, -1, 13, 2, -1, -1, 13, -1, 13, -1, -1, -1, -1, 29, -1, 65, 81, 53, -1, 7, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 27, 97, 17, -1, -1, -1, -1, 77, -1, 2, -1, 0, -1, -1, 44, 50, -1, 58, 49, 7, 12, 18, -1, 18, -1, 50, 5, -1, -1, 44, 127, -1, -1, -1, -1, -1, -1, -1, -1, 39, 12, -1, -1, 19, -1, -1, -1, -1, 2, -1, -1, -1, 22, -1, -1, 22, 66, 105, 2, 25, 153, 59, -1, 153, 162, -1, 25, -1, 111, 119, 120, 0, -1, -1, -1, -1, -1, -1, -1, -1, 13, -1, -1, 151, -1, -1, 151, 18, -1, -1, -1, 105, 91, 86, 50, -1, -1, 58, 20, 93, -1, 8, -1, 135, -1, -1, -1, 8, -1, 5, -1, 50, -1, -1, -1, 103, -1, 6, 140, 171, 45, 11, 5, -1, 43, 43, 127, -1, 79, 39, -1, -1, -1, -1, 129, -1, -1, 60, 0, -1, -1, 5, 60, -1, 91, 5, 18, -1, -1, 66, 120, -1, 110, -1, -1, -1, 46, -1, 17, -1, 127, 131, 37, 0, 151, 11, 0, -1, 4, -1, 46, 17, -1, 170, -1, 13, -1, 61, -1, -1, -1, -1, -1, 13, -1, 11, 2, 66, 27, 7, -1, -1, 11, -1, 7, 0, -1, 11, -1, -1, 50, 46, 27, -1, 22, 139, 40, -1, 61, 29, 11, 2, 5, -1, 17, 13, 11, -1, -1, 13, 13, 133, -1, 29, 13, 68, 133, 13, -1, 9, -1, 13, 13, -1, -1, 13, 13, 68, 13, 68, -1, -1, -1, -1, 13, 13, -1, 37, -1, -1, -1, 13, -1, -1, -1, 13, -1, -1, -1, -1, -1, 68, -1, 0, -1, 0, -1, 0, -1, 58, -1, 37, -1, 28, -1, 13, -1, 37, 0, 0, -1, -1, -1, 102, -1, 22, -1, 7, -1, 11, 19, -1, 105, -1, 129, -1, 27, -1, 7, -1, -1, 160, -1, 65, 31, -1, 5, -1, 7, 31, -1, 37, -1, -1, -1, 7, 37, -1, -1, 42, 2, 42, 42, 42, -1, 42, 42, -1, 42, -1, -1, 97, 124, 5, 15, -1, 42, 42, 52, -1, -1, -1, 52, 17, 11, 42, -1, 37, -1, 131, 2, 9, -1, 17, -1, -1, 151, -1, 7, 37, -1, 67, 7, -1, 18, -1, -1, 2, 11, 7, -1, 13, 13, -1, 22, 2, 13, -1, -1, 17, -1, 17, -1, -1, -1, 13, 35, -1, 68, -1, -1, 13, 127, -1, 4, 11, 13, -1, -1, 13, -1, -1, 68, 29, -1, -1, 13, -1, 2, 11, -1, -1, 1, 1, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1, -1, 1, 1, 2, 41, 1, 1, 1, -1, 1, 1, 1, 1, 1, 1, 1, 1, 53, -1, 1, 1, 1, 118, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 30, 10, 10, -1, -1, 10, -1, 30, -1, -1, 104, 30, -1, 10, -1, 10, -1, 10, -1, 10, 10, 10, 104, 10, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1, 25, 1, -1, 1, 1, 32, 1, 1, -1, 1, -1, -1, -1, -1, -1, 94, -1, -1, -1, -1, -1, 4, 4, 20, -1, -1, 20, -1, -1, -1, 8, 107, -1, -1, -1, 8, 8, 8, 15, -1, 9, -1, -1, 107, 2, -1, -1, 16, -1, 16, 16, 40, 16, 16, 16, 16, 16, -1, 78, -1, 16, 16, 16, -1, -1, 16, 16, 16, -1, 16, 78, 78, 16, -1, -1, 14, 72, 9, -1, 14, 14, 72, 168, 14, 29, -1, 14, 20, -1, -1, -1, 72, 14, 14, -1, 121, 14, 10, 14, 30, 14, 9, 14, 72, -1, 14, 10, 4, 14, -1, -1, 41, 14, 2, 14, 72, 53, 14, 14, 14, -1, 2, 14, 14, -1, 10, -1, 19, -1, -1, 12, -1, 56, 60, 7, -1, -1, 5, -1, 8, 17, 56, 2, -1, -1, -1, 4, 20, 56, 56, 3, 93, -1, 75, 94, 56, 56, 93, 93, 152, -1, -1, -1, 3, 56, -1, -1, -1, 4, 94, 5, -1, -1, 8, 56, 46, -1, -1, -1, 4, -1, 13, 156, 10, 80, 8, -1, 21, 5, 117, -1, 21, 21, -1, 21, 21, 21, -1, -1, -1, -1, 56, -1, 21, 58, 5, 64, 13, -1, -1, 11, 31, -1, -1, 62, -1, 11, 10, -1, -1, -1, -1, 10, 10, -1, -1, 5, 30, 10, 10, 10, -1, 30, 10, 10, -1, 88, 88, -1, 10, 41, -1, 10, -1, 10, 21, -1, -1, 2, -1, -1, -1, 3, -1, -1, 52, 2, 2, -1, 70, -1, 21, 52, 21, -1, -1, 42, 52, -1, -1, -1, -1, 64, -1, -1, 2, 136, 5, 87, 22, 122, 56, -1, -1, -1, 122, 64, 59, -1, 56, -1, 80, -1, 4, 56, 80, 2, 12, 113, 56, 70, -1, -1, -1, 57, -1, -1, -1, 8, -1, -1, -1, 81, 106, 102, 106, -1, -1, -1, 128, 128, -1, 12, 10, -1, -1, 31, -1, 31, -1, 152, -1, 102, 30, -1, -1, -1, -1, 26, -1, 10, 10, 10, 88, -1, 10, -1, 68, 26, -1, 26, 104, 118, 13, 66, 12, -1, -1, -1, 172, -1, -1, -1, -1, 44, -1, 141, 22, 53, -1, 2, -1, 4, -1, 14, 35, -1, -1, -1, -1, 11, -1, -1, -1, 27, 22, 21, -1, 2, -1, -1, -1, -1, -1, -1, -1, 10, 94, -1, 14, 10, 30, -1, 10, 62, 10, 10, -1, -1, 62, 10, -1, -1, -1, 41, -1, 4, 14, 14, 18, 103, -1, -1, 2, -1, 8, -1, 8, -1, 62, -1, -1, -1, 8, -1, 8, 5, 8, 8, -1, 135, 62, 8, 22, 8, 8, -1, 8, -1, 8, 14, 8, 8, 8, 8, 8, 8, 8, 46, 8, 8, 8, 135, 17, 99, 65, -1, 34, 8, 46, -1, 8, 34, 65, -1, -1, 118, 104, 30, 10, -1, 10, 10, -1, -1, -1, 118, -1, 10, -1, 26, 10, 10, -1, 30, 30, -1, -1, 5, 118, 104, -1, -1, 10, 14, 10, -1, -1, -1, 20, -1, -1, -1, 94, -1, 26, -1, 25, 10, 14, 14, 14, 14, 29, -1, -1, 14, -1, 14, 72, -1, -1, -1, 36, 97, 11, -1, -1, 35, -1, -1, 30, -1, 12, 156, 11, -1, -1, -1, 8, 29, -1, 135, 21, -1, 4, -1, 41, -1, 21, 8, 4, -1, -1, -1, 40, 58, 12, 12, 7, 12, 99, 7, 7, 12, 12, 2, 5, 12, -1, -1, 2, 19, -1, 65, -1, 5, 5, 65, -1, 12, -1, 17, 66, 21, -1, -1, 7, 66, 5, 2, -1, 0, 7, 44, 15, -1, 5, -1, -1, -1, 77, -1, 11, -1, 9, 17, 11, -1, 113, 11, -1, -1, -1, -1, -1, 8, 8, 8, 8, 8, -1, 17, 5, -1, -1, 15, 4, 4, 4, 4, 4, 4, 4, 31, 4, 4, -1, 4, 4, 4, 4, 4, 4, 4, 4, 4, -1, 12, 4, 4, 4, 4, -1, 5, -1, 12, -1, 2, -1, 77, -1, 22, 46, 5, 8, -1, 7, 127, 35, -1, -1, -1, -1, 103, 171, -1, 70, 5, 46, 8, 97, 102, -1, 31, 31, 25, -1, 4, -1, -1, 46, 46, -1, 46, 46, 127, 46, 44, 116, -1, -1, -1, -1, -1, -1, -1, -1, 62, -1, -1, -1, 134, 65, 7, -1, -1, 11, 12, 12, 19, -1, 134, -1, -1, 12, -1, 35, -1, 7, 19, 52, 46, 65, 20, 30, 30, -1, 5, -1, -1, 33, -1, 160, -1, 30, 36, -1, -1, -1, -1, -1, -1, -1, 85, -1, 30, -1, -1, -1, 10, 33, -1, -1, -1, 25, -1, 35, -1, -1, -1, -1, -1, -1, -1, -1, -1, 4, 19, -1, 42, 12, 19, 17, -1, 85, -1, 99, 19, -1, -1, 19, -1, 5, 4, -1, 53, 12, -1, -1, 5, -1, 7, 80, 80, -1, -1, 12, 42, 99, 12, 12, -1, 12, -1, 5, 12, -1, 4, -1, 8, 19, -1, 12, -1, -1, -1, 4, -1, -1, -1, -1, 35, -1, -1, 70, -1, 19, -1, -1, 17, 35, -1, -1, 166, -1, -1, 7, 5, 2, -1, -1, -1, -1, -1, -1, 17, 9, -1, 34, -1, 7, 5, 7, 4, 37, 19, -1, -1, 2, -1, -1, -1, -1, -1, -1, 4, 31, -1, 4, -1, -1, 31, 12, 35, 52, 12, 12, -1, 11, 17, -1, -1, 31, -1, 12, 2, -1, 99, 5, -1, -1, 22, -1, 5, 11, 139, -1, -1, 67, 15, 3, 27, -1, 149, -1, 17, 21, -1, 21, -1, 70, 80, -1, 17, 3, -1, 30, 8, 11, 12, -1, 3, -1, -1, 124, 19, 2, 19, 97, 124, 12, -1, -1, -1, 7, -1, -1, -1, 7, -1, 8, -1, -1, 12, 12, -1, -1, 7, 2, 27, -1, 2, -1, -1, 8, -1, 29, -1, 12, 12, 12, -1, -1, 134, 22, 11, 134, 2, -1, 11, -1, 12, -1, 22, -1, -1, -1, 46, -1, 141, -1, -1, 46, 38, 2, 156, 38, -1, -1, -1, 8, 4, -1, 93, 4, 113, 4, -1, 11, -1, 15, 11, 113, 20, -1, 2, -1, 68, 29, 17, -1, -1, -1, -1, 149, 8, 93, -1, -1, 17, 52, 173, 173, 173, 173, 35, 5, 62, 8, -1, 7, 4, 5, -1, 2, 5, 7, 2, -1, 62, -1, -1, -1, -1, -1, -1, -1, -1, 125, 141, -1, 62, -1, 15, 4, -1, -1, -1, -1, -1, 34, 18, -1, -1, 19, 160, 170, 42, 106, -1, 7, -1, 81, -1, -1, 160, -1, -1, 12, -1, 65, -1, 10, -1, 19, -1, 53, 12, -1, 11, 12, 5, -1, 12, 11, 12, -1, -1, -1, -1, 52, 12, -1, -1, 19, 8, 2, -1, 4, -1, 29, 81, -1, 21, -1, 52, -1, -1, -1, 67, 2, 8, 97, 29, -1, 81, 30, -1, -1, 17, 14, -1, -1, 102, -1, -1, 2, 5, -1, -1, 2, 49, 27, -1, 31, -1, -1, -1, -1, -1, -1, -1, -1, -1, 37, -1, 94, 17, 33, 17, -1, -1, 53, -1, -1, -1, 4, -1, -1, 1, -1, -1, 1, -1, -1, 14, -1, -1, -1, -1, -1, -1, -1, -1, 9, 1, 48, -1, -1, 21, -1, -1, -1, -1, -1, 10, -1, -1, -1, -1, -1, -1, 7, 8, -1, 10, -1, 10, 3, 19, -1, 14, 46, 20, -1, -1, 3, -1, 3, 3, -1, 10, 10, 10, -1, -1, -1, 173, -1, -1, 3, 56, 25, 3, 5, -1, -1, -1, 54, 3, 14, 10, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 29, 4, 4, 4, -1, -1, 17, 14, 5, 2, -1, -1, -1, -1, -1, 52, -1, 62, -1, 7, -1, -1, 156, -1, 5, -1, 29, -1, -1, 152, -1, 18, -1, -1, -1, 17, 67, 3, -1, 8, 116, 8, 46, 124, 7, 17, 2, 2, 35, 74, -1, -1, 2, 1, 37, -1, 135, -1, -1, -1, 18, 49, 0, 17, -1, 74, 49, 31, 31, 31, 31, 31, 31, 4, 58, 7, 53, -1, 4, -1, -1, 93, 4, -1, 35, 9, 4, -1, -1, 8, -1, 102, 27, -1, -1, 4, 105, -1, 62, 4, -1, 29, 85, 53, 17, 17, 3, 4, -1, 5, 7, 36, -1, 44, 52, 12, 15, 113, 5, 5, 7, -1, 2, 37, -1, 2, 15, -1, 40, -1, 8, 105, -1, 8, 50, 152, -1, -1, -1, 92, 7, -1, 10, 4, 5, -1, -1, 2, -1, -1, 61, -1, -1, -1, 21, 21, -1, -1, 36, -1, -1, 3, -1, 2, -1, 2, -1, -1, -1, 142, 41, -1, -1, -1, -1, -1, 118, -1, -1, 117, -1, 14, 41, -1, 142, 142, -1, 72, -1, -1, 71, -1, -1, -1, 49, -1, -1, -1, 63, 15, -1, 10, -1, -1, 5, 143, -1, -1, 26, -1, 10, -1, -1, -1, -1, -1, -1, -1, -1, 111, -1, -1, -1, 15, -1, 6, -1, 54, 54, 119, 119, 54, -1, 54, 32, -1, 3, -1, -1, -1, 54, 1, 1, 20, 158, -1, -1, -1, -1, 2, -1, 14, -1, 72, -1, 84, -1, -1, -1, -1, -1, -1, 34, -1, -1, 4, 4, -1, -1, -1, 34, 163, -1, -1, 34, 5, 2, 148, 163, -1, 11, -1, 7, -1, -1, -1, -1, 48, -1, 84, -1, 34, 34, 9, 84, -1, -1, 71, -1, -1, 34, -1, 28, -1, -1, -1, -1, 48, 14, -1, 26, -1, 26, -1, -1, -1, -1, -1, -1, -1, 26, 1, -1, -1, -1, 9, 26, -1, -1, -1, 26, -1, -1, -1, -1, 90, -1, 26, 26, -1, 88, 26, 26, 26, -1, 26, -1, 26, -1, -1, 112, 32, 26, 90, 26, 1, 3, 41, 26, 28, 37, 67, -1, 0, -1, 21, 3, -1, 168, 67, 11, -1, -1, 39, -1, 28, 7, 4, -1, 30, -1, 5, -1, 99, 12, 52, -1, -1, 13, 29, 14, 10, 3, -1, -1, -1, -1, 2, -1, 18, 35, 49, 49, 5, 11, -1, 12, -1, 19, 12, 19, 35, -1, 7, 7, -1, -1, 81, 12, 8, -1, 12, 19, 62, 36, 64, -1, 43, -1, -1, -1, -1, -1, 87, -1, 112, -1, -1, 21, -1, 21, 117, 117, -1, 7, 21, 21, -1, 21, -1, -1, 51, 18, 128, 81, -1, 7, -1, 106, 170, 7, -1, 4, 102, -1, 170, -1, -1, 4, 81, 22, 128, 7, 7, 4, 4, -1, 42, -1, 81, 81, 87, -1, -1, 0, 51, -1, 51, -1, -1, -1, -1, -1, -1, 87, 51, 51, -1, 9, 66, -1, -1, -1, 165, 23, -1, -1, -1, 109, 7, -1, 120, -1, 140, 0, -1, 37, -1, -1, -1, -1, 13, -1, -1, -1, 5, -1, 11, -1, 144, 144, 28, 0, 0, 0, 0, 0, 82, 0, -1, -1, -1, 78, -1, -1, -1, 78, 78, -1, 78, 28, 28, 28, 117, 0, -1, 0, -1, -1, 0, -1, 0, 39, -1, 86, 64, 39, 0, 0, 0, -1, -1, 0, -1, 18, 0, -1, 0, 0, 0, 0, 0, -1, -1, -1, -1, 0, 92, 0, 92, -1, -1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 92, 64, -1, 0, 64, 0, -1, 0, 0, 108, 0, 0, 0, -1, 0, 0, 79, 0, 0, 0, -1, -1, 0, 92, 0, 0, 0, 0, 0, -1, -1, -1, 0, 0, 0, 0, 0, 0, -1, -1, 0, -1, 0, 108, 0, 0, -1, 0, -1, 0, 0, -1, -1, 0, -1, -1, 0, 119, -1, 108, 11, 0, 0, -1, 7, -1, 0, 0, -1, 92, -1, -1, 79, -1, -1, 86, -1, 0, -1, 2, -1, 0, 0, -1, -1, -1, 0, 0, -1, 0, 0, 0, 137, 0, -1, 51, -1, -1, -1, 51, 92, -1, 0, 0, -1, 28, 28, 28, 28, 0, 117, 0, 0, 0, 78, -1, 16, -1, 16, 28, 16, -1, -1, 117, 28, -1, 16, 28, 7, -1, -1, -1, 101, 28, -1, -1, 162, 5, 50, 66, -1, 66, 37, -1, 6, 19, -1, 36, 40, -1, -1, 67, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 0, 145, 0, 0, 0, 0, 0, 0, 0, 0, -1, 0, 0, 145, 0, 0, 0, 0, 0, 0, 0, 0, 145, 0, 0, 0, 0, 0, 0, 39, 0, 0, 0, 0, 0, 0, 0, 0, 145, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 144, 0, 0, 0, -1, 0, 0, -1, -1, 0, 0, 0, 0, -1, 0, 0, -1, -1, 0, 0, 64, -1, -1, -1, 0, 0, -1, 60, 0, 79, -1, 22, 0, -1, -1, -1, -1, -1, 0, 0, -1, 146, -1, 0, 0, 0, 43, -1, 0, 22, -1, 95, 0, 0, -1, 0, 0, 116, -1, 0, 0, -1, 0, 0, 0, 0, -1, -1, -1, -1, -1, 131, 19, -1, -1, 4, -1, 43, -1, 120, -1, 43, 45, -1, 171, 2, 23, -1, 22, -1, 53, 2, -1, -1, -1, 1, 61, 31, 36, -1, -1, -1, -1, 36, 31, -1, -1, -1, -1, -1, 38, -1, -1, 165, -1, -1, 5, 100, 100, 6, 6, 89, -1, -1, 0, 0, 0, 0, 0, 0, -1, -1, 0, 0, 5, 145, 0, 0, -1, 0, 0, -1, -1, 169, -1, 0, 138, -1, 0, -1, 0, -1, -1, 0, 0, 0, 0, -1, 0, 0, -1, 0, -1, -1, 0, 0, 0, 0, 0, 0, -1, -1, -1, -1, 76, 0, 0, 0, 0, 0, 137, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 109, 0, 0, 0, 0, 0, 0, 0, 0, 65, 0, 0, 0, 0, -1, -1, 5, 2, 66, -1, 7, 86, -1, -1, -1, 101, 37, -1, 57, -1, 79, -1, 2, 120, -1, 59, -1, 122, -1, -1, 65, 109, -1, 60, -1, 17, -1, -1, -1, -1, -1, 44, -1, 126, 22, 60, -1, 91, -1, 122, 54, -1, 6, -1, -1, 38, 89, -1, 45, 100, 36, 64, 6, 6, 69, 45, -1, -1, 6, -1, 75, -1, 36, -1, -1, -1, -1, 6, -1, -1, -1, 3, -1, -1, 9, 2, 6, -1, 2, 154, 89, 89, -1, -1, 89, -1, -1, -1, -1, 6, 66, 6, -1, 100, 64, -1, -1, -1, 6, -1, -1, 110, 6, -1, 86, 6, 60, 122, 83, 45, 6, 45, 83, 69, -1, -1, -1, -1, 45, -1, 6, -1, -1, 6, 69, 6, 54, -1, -1, 83, 39, -1, 64, 86, 45, -1, -1, 30, 129, -1, -1, 90, 22, -1, 105, -1, 6, 39, 45, -1, 35, -1, 1, -1, -1, 6, -1, 69, -1, 80, 36, -1, 130, 6, -1, 89, 6, -1, 3, 43, -1, 22, 36, -1, 6, -1, 91, 45, -1, -1, -1, 56, 56, 75, 4, 56, -1, 69, -1, 3, -1, 83, 18, -1, -1, 36, 111, 69, 25, 0, -1, 83, 86, 86, 0, 69, -1, -1, -1, -1, 27, -1, -1, 78, 7, 5, 69, 5, 69, -1, -1, 9, 125, 36, -1, -1, -1, 91, -1, 37, -1, 100, 64, -1, 3, 6, 70, 23, -1, 23, -1, 115, 51, 115, -1, 23, 43, -1, 23, -1, -1, -1, -1, 5, 89, 6, -1, 6, -1, 89, -1, -1, -1, -1, 6, -1, -1, -1, -1, -1, 36, 6, -1, -1, -1, -1, -1, 6, -1, 36, 36, -1, 75, 100, -1, 3, 69, 57, -1, 0, 59, 6, 6, 36, -1, -1, 89, 55, -1, 45, -1, -1, -1, 5, 6, -1, 23, -1, 6, -1, 75, -1, 57, -1, 119, -1, 54, 22, -1, 5, 9, -1, 86, -1, 56, -1, -1, 69, -1, 6, 6, 83, -1, 2, 11, -1, -1, 83, -1, -1, 138, 0, 91, 23, 57, 110, 122, -1, -1, 8, 6, -1, 6, 6, -1, -1, 6, -1, 91, 91, -1, 75, 6, 45, 45, -1, 126, -1, 2, -1, 13, -1, -1, -1, -1, -1, 26, -1, -1, -1, 48, 10, 5, -1, -1, 26, 20, -1, 26, 150, -1, -1, 25, 90, -1, 90, 90, -1, -1, -1, 90, 90, -1, -1, -1, 0, -1, -1, 3, -1, -1, -1, 137, 0, 108, -1, 60, -1, 7, -1, -1, -1, 7, -1, 19, -1, -1, -1, 77, -1, -1, 77, 7, 7, 77, -1, -1, -1, 7, -1, -1, 15, 7, 15, 17, 7, 11, -1, -1, -1, 7, -1, -1, -1, -1, 77, 7, 17, 7, -1, 0, -1, 0, 69, 69, -1, -1, -1, 114, -1, 114, -1, -1, 0, 0, 0, 0, -1, -1, 0, -1, 0, 0, -1, 0, 0, -1, 0, 0, -1, 143, -1, -1, 1, 53, 25, -1, 1, 5, 82, -1, -1, -1, 1, -1, 3, 1, 1, 1, -1, 1, 1, 1, 1, 53, -1, -1, -1, -1, 80, 110, 43, 3, -1, 36, -1, -1, 12, -1, 29, 57, -1, -1, 3, 3, -1, 35, -1, 142, 29, -1, 0, -1, 0, 0, -1, -1, 169, 79, -1, 0, -1, -1, -1, 114, -1, 2, -1, -1, 62, 0, -1, -1, 116, 55, -1, -1, -1, 9, -1, -1, -1, 2, -1, 74, -1, 34, 74, -1, -1, 12, 74, -1, 2, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 2, 85, 85, 85, 85, -1, -1, 84, -1, -1, -1, 11, 2, -1, -1, 34, 40, -1, -1, -1, -1, -1, -1, 48, -1, 48, -1, 48, 48, -1, -1, 84, 48, -1, 48, 15, -1, 48, 48, 48, 48, 48, 48, -1, 48, -1, -1, -1, -1, 30, -1, -1, 48, 5, -1, 63, 9, -1, -1, 22, -1, 15, -1, -1, 9, -1, 15, 9, -1, -1, -1, -1, 39, 85, -1, 20, 37, -1, -1, -1, 11, -1, -1, -1, -1, 32, 32, -1, -1, 32, 32, 32, 32, 32, 32, -1, 1, 16, -1, -1, -1, -1, -1, -1, 164, 164, -1, -1, -1, 40, -1, 25, 32, 32, 32, -1, 1, 32, 32, -1, 32, -1, 32, -1, -1, -1, -1, 0, 30, -1, 20, 20, 20, 20, 20, 172, 121, 72, -1, -1, 18, -1, -1, -1, -1, 72, 72, -1, 9, 15, 34, 121, 25, -1, -1, -1, 1, 1, 9, 1, 1, 1, 1, 1, 1, 1, 1, -1, 1, 1, 1, 1, 1, -1, 1, 1, 1, 1, 1, 1, 1, -1, 136, 0, 5, -1, -1, 88, 136, -1, -1, -1, 40, -1, 1, -1, -1, -1, -1, -1, -1, 165, 6, 6, 6, -1, 6, 6, -1, -1, 6, -1, 28, 20, 28, -1, -1, 9, 9, 100, 92, 5, 5, -1, -1, -1, -1, -1, 78, -1, -1, -1, -1, 105, 20, 43, -1, -1, -1, 12, 109, 55, -1, 55, 110, 55, -1, 41, 43, -1, 55, -1, -1, 43, -1, -1, -1, -1, -1, 87, -1, 12, -1, 167, 55, -1, -1, -1, 108, 146, -1, -1, -1, -1, 23, -1, 130, 55, 55, 115, -1, 23, 109, -1, -1, 43, 23, 55, 23, -1, 23, 23, -1, 23, 23, 23, 23, 43, 23, -1, 55, 23, 43, -1, 23, 23, 23, -1, 55, 23, 23, -1, 23, 4, 23, -1, -1, -1, 23, -1, -1, -1, 26, 26, 5, -1, 26, -1, -1, 4, -1, -1, -1, 71, 10, 10, 90, -1, -1, -1, -1, -1, 90, 90, 2, -1, 26, -1, -1, -1, 23, 23, -1, -1, -1, -1, -1, -1, -1, 43, -1, -1, 23, 109, 55, -1, -1, 55, -1, 57, -1, 23, 51, -1, -1, 22, 0, 120, 167, 41, 55, -1, -1, 146, 108, 23, -1, 167, 3, -1, -1, -1, -1, -1, -1, -1, 38, -1, -1, -1, -1, -1, 41, -1, -1, 54, -1, -1, 38, 0, 0, 0, 0, 0, 0, 0, 40, 0, 0, 0, 0, 0, 16, 169, 0, -1, 0, 0, 0, -1, -1, 0, -1, -1, 51, 140, -1, 78, 64, -1, -1, 9, -1, -1, -1, 51, 18, 0, -1, 58, 22, -1, 0, -1, -1, 5, 57, -1, 116, -1, -1, -1, -1, -1, 39, 19, 4, 108, -1, 7, 79, 5, 79, -1, -1, -1, -1, -1, -1, 41, -1, -1, -1, -1, -1, 41, 167, -1, 41, -1, -1, -1, 115, 45, -1, -1, -1, -1, 115, -1, -1, -1, 115, -1, -1, 46, -1, -1, -1, -1, -1, -1, 46, 38, 64, 88, -1, -1, -1, -1, 147, 38, -1, 87, 116, -1, 6, 6, 6, 6, 62, -1, -1, -1, 47, 28, -1, 47, 132, -1, -1, -1, -1, 95, 34, -1, -1, -1, 71, -1, -1, -1, -1, 59, 71, -1, 20, -1, 85, 26, -1, 84, -1, 22, -1, -1, 132, -1, -1, -1, 72, -1, 48, 48, -1, -1, -1, -1, 26, 95, 34, -1, 14, 1, -1, 26, 10, 30, -1, 40, -1, 10, -1, -1, 10, -1, -1, 95, 98, -1, -1, 59, -1, -1, -1, -1, -1, 0, 0, 0, 0, 0, 95, 0, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, 103, -1, -1, 98, 9, 8, -1, 9, -1, -1, -1, -1, 16, -1, 72, -1, 143, -1, -1, -1, -1, 138, 105, -1, 51, -1, -1, 146, 87, 146, 87, -1, -1, 51, -1, -1, 130, 146, -1, -1, -1, 66, -1, 58, 61, 7, 148, -1, -1, -1, -1, 103, -1, 15, 161, -1, 58, -1, -1, 3, 8, -1, -1, -1, 58, 7, -1, -1, -1, 44, 44, -1, -1, -1, 44, 44, 2, 44, 44, -1, 99, 1, -1, 161, 1, -1, -1, 38, 71, -1, 40, -1, -1, 55, 130, 154, -1, 4, -1, -1, -1, -1, 4, -1, -1, 38, -1, 8, -1, -1, -1, 2, 77, 114, 114, 59, 30, -1, -1, 11, -1, -1, -1, -1, -1, -1, -1, 8, -1, 159, 79, 114, 54, -1, 16, -1, -1, -1, -1, -1, 109, 123, -1, -1, -1, 87, 146, -1, -1, 23, 64, 30, 154, -1, 2, -1, -1, 57, -1, 109, 2, 2, 6, 2, 6, 6, 6, 57, 6, 6, -1, 31, -1, -1, -1, 11, -1, 39, 41, -1, -1, 18, -1, 93, -1, 8, 46, -1, 8, 62, -1, -1, -1, 2, 11, 5, 21, 35, 70, 70, 70, -1, -1, -1, 15, 15, -1, 49, -1, 1, 49, 49, -1, 49, 25, 49, 70, 12, 11, 11, 21, -1, -1, -1, -1, 144, -1, -1, -1, -1, -1, -1, 38, -1, -1, 59, 58, 54, 154, -1, 95, -1, 88, -1, 103, -1, 8, -1, -1, 60, -1, -1, -1, 19, -1, -1, -1, 95, -1, 55, -1, -1, 38, 100, 9, -1, -1, -1, 16, -1, -1, -1, -1, 4, 1, 59, -1, -1, 158, -1, -1, -1, 92, 9, -1, 147, 41, -1, 144, 38, -1, -1, -1, -1, -1, -1, 4, -1, -1, -1, 60, -1, -1, -1, -1, 9, -1, 60, 27, -1, 138, -1, -1, -1, 9, 18, 6, 6, 6, -1, 6, 6, -1, -1, 16, 100, -1, 59, 9, -1, 149, -1, -1, 42, 110, 114, 130, 8, -1, -1, -1, 3, -1, 3, 5, -1, -1, -1, 59, -1, 5, -1, -1, 6, -1, -1, -1, 98, -1, -1, 6, -1, -1, 6, -1, -1, 16, 154, -1, -1, 59, -1, -1, -1, -1, -1, -1, -1, -1, 41, -1, -1, 17, -1, 38, 120, -1, -1, 108, -1, -1, 0, 0, -1, 60, -1, -1, 0, -1, 58, -1, 0, 145, 116, 0, 5, 0, 8, 0, -1, 69, -1, -1, -1, -1, 17, -1, 2, 156, 13, -1, 11, 74, -1, 74, 44, 74, 147, -1, -1, 2, 74, -1, -1, 16, 96, 101, -1, -1, -1, 96, -1, 40, -1, 5, 96, -1, -1, -1, -1, -1, 108, 58, 110, 0, 64, 38, -1, -1, 60, 22, -1, -1, 0, 2, 114, -1, 145, -1, 123, 123, 123, 5, -1, 0, 123, -1, -1, 123, -1, 114, 79, 134, 12, -1, -1, -1, -1, 59, -1, -1, -1, -1, -1, 12, -1, 20, 0, -1, -1, 123, -1, 0, 38, -1, 38, 111, -1, 22, 147, -1, -1, -1, 9, 38, 92, -1, -1, -1, -1, 144, 79, 41, -1, 100, 22, -1, -1, -1, -1, 13, -1, 89, -1, -1, -1, -1, -1, -1, -1, 9, -1, 9, 4, 38, 66, -1, -1, -1, 2, 132, -1, 6, -1, -1, -1, 2, -1, 58, -1, 18, 6, -1, -1, -1, -1, 2, -1, -1, 12, 35, 4, 4, 80, 11, 4, 4, 4, -1, -1, 4, -1, -1, 12, 12, 4, 4, -1, 4, 4, 44, 85, 4, -1, -1, -1, -1, -1, -1, 118, 50, -1, -1, -1, -1, -1, -1, -1, -1, -1, 6, 6, -1, 10, -1, -1, 95, -1, 34, -1, 54, -1, 111, -1, -1, -1, 95, -1, -1, 150, 16, -1, -1, 132, 95, 95, -1, 34, -1, 47, 111, 121, 9, 132, -1, -1, 98, -1, -1, -1, -1, -1, -1, -1, 144, -1, 1, 34, -1, 22, -1, -1, 59, -1, 158, 150, -1, -1, -1, 54, -1, -1, 1, -1, 2, -1, -1, 0, -1, 84, -1, -1, 53, -1, -1, -1, 40, -1, -1, 4, 9, 20, -1, -1, 71, -1, -1, -1, -1, 47, 1, 33, -1, 82, 33, -1, 73, 47, 113, -1, -1, -1, -1, -1, 73, -1, 33, 47, -1, -1, 4, 73, -1, -1, -1, 33, 82, 19, 33, 1, 82, 82, 82, 33, 33, 82, 73, 33, -1, 33, -1, -1, -1, -1, 33, 47, -1, -1, 12, 12, 19, 73, -1, 33, -1, -1, -1, -1, -1, 73, -1, 82, 1, 1, 1, 1, -1, 1, -1, 4, -1, -1, 47, -1, -1, -1, 47, 47, -1, 16, 33, 19, 8, 47, -1, -1, -1, 47, -1, -1, -1, -1, -1, -1, 1, -1, -1, 33, 82, -1, 9, -1, -1, 82, -1, 47, 5, -1, -1, 157, -1, 157, -1, 106, 112, -1, -1, -1, 35, 88, 112, -1, 118, -1, 84, -1, 33, 73, 33, 2, 115, 8, -1, -1, -1, 47, -1, -1, 98, 98, -1, 159, -1, -1, -1, -1, 35, -1, -1, -1, 41, 41, 41, 47, 33, 9, -1, -1, -1, 76, -1, -1, 11, 76, -1, -1, -1, -1, -1, -1, -1, -1, -1, 34, 16, -1, 84, -1, -1, -1, 103, 2, 76, 153, -1, -1, 107, -1, -1, 9, -1, -1, -1, -1, 3, -1, -1, 1, -1, -1, 22, 20, 20, -1, 76, -1, 34, -1, -1, -1, 112, 9, 9, 164, 20, 9, -1, 17, 77, -1, 172, -1, -1, -1, 20, 148, 2, 9, -1, 75, 5, -1, 40, -1, 72, 25, 40, -1, -1, -1, -1, -1, -1, -1, -1, -1, 121, -1, -1, -1, 75, -1, -1, -1, 112, -1, 112, -1, 90, 5, 1, 12, -1, 12, -1, 99, 19, -1, -1, 1, 20, 71, 4, 157, 33, 73, 73, -1, 8, 25, -1, 0, -1, -1, -1, -1, -1, -1, 33, 12, 47, -1, 47, -1, 82, -1, -1, 30, -1, -1, -1, -1, 0, 154, 38, 0, -1, -1, -1, 98, -1, -1, -1, -1, -1, 46, 151, -1, 50, 122, -1, 162, -1, 6, 45, 43, -1, -1, 25, -1, -1, -1, 66, 19, 60, 6, 45, 89, -1, 3, -1, 12, -1, -1, -1, 87, -1, -1, -1, -1, 98, -1, -1, -1, -1, -1, -1, 115, -1, -1, 51, -1, -1, -1, 109, 23, -1, -1, 87, 41, -1, 109, -1, 18, 27, 6, 2, 6, 134, 77, 0, -1, 103, 1, 1, -1, -1, 1, -1, -1, -1, 143, -1, -1, 29, -1, 10, 14, -1, 10, 5, 7, 81, 31, 56, 4, 8, 31, -1, 126, 113, 128, -1, 121, -1, 49, 49, -1, -1, -1, -1, 7, 19, 18, 152, 0, -1, 30, 0, -1, 8, -1, 2, 18, 81, 8, -1, -1, -1, -1, -1, 29, 4, 143, -1, 42, -1, 85, 127, 53, 166, -1, -1, 3, 7, -1, 106, 14, 135, 12, -1, -1, 52, 7, 52, -1, -1, -1, 9, 42, 4, 29, 8, 8, 8, 8, 2, 8, -1, -1, -1, -1, 73, 10, 2, -1, -1, -1, 20, -1, -1, -1, 48, 48, 1, -1, 26, 26, 10, -1, -1, 10, -1, -1, 71, 143, -1, -1, -1, 104, -1, 10, -1, 18, 139, 21, -1, -1, -1, 19, 80, 104, 104, 88, 30, 10, 4, 17, -1, 26, 112, -1, -1, -1, 163, 40, -1, 20, 3, 32, 32, 32, 4, 75, -1, -1, -1, 17, 96, 9, -1, 35, 2, -1, 7, -1, -1, 126, -1, 148, -1, 70, 147, 101, 91, 18, 148, 18, -1, 13, 65, 133, -1, -1, -1, -1, 29, 131, 27, 27, -1, 140, -1, -1, -1, 0, 0, 0, 0, 0, 0, 0, 0, 39, 0, 0, 0, 0, -1, -1, 8, 31, 63, 113, -1, 2, -1, 3, 3, -1, 3, 48, -1, -1, -1, -1, 2, 34, -1, 3, 30, 166, -1, 4, 19, 12, -1, -1, 25, -1, 1, 1, 1, 25, 1, -1, -1, 4, -1, -1, -1, -1, -1, -1, 27, 0, 0, 0, -1, -1, 28, 18, 0, -1, -1, -1, -1, 61, -1, -1, 18, 4, 15, 8, 3, 7, -1, -1, 4, -1, -1, -1, -1, 61, 39, 5, -1, -1, -1, -1, 9, -1, -1, -1, 9, -1, -1, -1, -1, 7, -1, 63, 63, 2, -1, 3, 3, 3, -1, -1, 3, 3, 2, 3, 15, 3, 66, 3, -1, 3, 3, 3, -1, 3, 3, 3, 1, -1, 3, 3, -1, 3, 21, -1, 94, -1, 3, 15, -1, 61, -1, 39, -1, -1, 3, -1, 2, -1, -1, 3, -1, -1, -1, 7, 67, 1, -1, -1, -1, -1, -1, 2, 22, 4, 37, -1, 116, -1, -1, -1, -1, -1, -1, -1, 8, -1, 3, 97, -1, -1, -1, 49, 70, -1, -1, 49, -1, 49, -1, 49, 15, 2, 11, 5, -1, -1, 49, -1, -1, 49, -1, 15, -1, 70, -1, 44, 161, -1, 2, -1, 84, -1, -1, -1, -1, -1, 30, -1, 94, -1, 94, 104, -1, -1, 143, -1, -1, -1, -1, 71, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 3, -1, -1, 40, 7, -1, 31, -1, 7, -1, -1, -1, 94, 15, 67, -1, 27, -1, 52, 7, -1, 18, 40, -1, 17, -1, 39, -1, 76, 39, -1, -1, -1, -1, -1, 39, -1, 5, -1, 11, -1, -1, -1, 28, -1, -1, -1, -1, -1, -1, 1, -1, 163, -1, 63, 1, 107, -1, -1, 2, -1, -1, -1, 68, -1, 9, 53, -1, 61, -1, -1, -1, 3, -1, -1, 19, -1, 13, 9, -1, -1, -1, 9, -1, -1, -1, -1, -1, -1, 3, 28, 2, -1, 18, 96, -1, -1, 13, -1, -1, 13, -1, -1, -1, -1, 131, 13, -1, 129, 58, -1, -1, -1, 15, -1, -1, -1, -1, -1, -1, 164, -1, 71, -1, -1, -1, -1, 34, 28, -1, -1, -1, -1, -1, -1, 5, 2, 2, 2, 1, -1, -1, 2, 96, -1, -1, 11, 2, 7, -1, 17, -1, -1, -1, 27, -1, -1, -1, 7, -1, 155, -1, 9, -1, -1, -1, -1, -1, -1, -1, 3, -1, -1, -1, -1, 61, -1, 9, -1, 125, -1, -1, -1, -1, 15, -1, -1, -1, 13, 28, 59, 57, 4, 16, 18, 27, -1, 132, -1, -1, -1, -1, -1, 38, 66, -1, 14, 3, -1, 64, -1, -1, 28, -1, -1, 13, -1, -1, -1, -1, -1, 3, -1, -1, -1, 14, 6, -1, 6, 6, 27, 11, 155, -1, 67, -1, 11, 11, -1, 2, 53, 29, 142, 2, 2, 58, -1, 11, -1, -1, -1, 27, -1, -1, 2, 3, -1, -1, -1, -1, -1, -1, -1, 61, 61, -1, 141, -1, 39, 61, -1, 31, 3, -1, 111, -1, -1, 28, -1, -1, -1, -1, -1, -1, 53, 54, -1, 32, 34, 6, -1, -1, -1, -1, -1, -1, 6, -1, -1, -1, 54, 5, -1, -1, 163, 74, 40, -1, -1, 15, 2, -1, 76, 153, -1, -1, -1, 2, 77, 6, 6, 125, -1, -1, -1, -1, 27, 6, 3, -1, -1, 94, -1, -1, 32, -1, -1, -1, -1, 32, -1, -1, 32, 3, 32, 13, -1, -1, 16, 16, -1, 18, 16, 11, 16, 79, 16, 16, 78, -1, -1, 78, 16, 16, 63, 63, 3, 53, 3, 3, -1, 3, 3, 53, -1, 3, 3, 2, 3, 3, 6, -1, 3, 3, 9, 3, -1, -1, 3, 2, 16, 3, 15, 15, -1, 15, -1, 20, -1, -1, -1, -1, -1, -1, -1, -1, 15, -1, 8, -1, 3 ], "topic_sizes": { "5": 120, "-1": 3778, "33": 29, "7": 110, "41": 25, "113": 9, "0": 429, "57": 21, "1": 186, "24": 38, "21": 41, "171": 5, "9": 92, "20": 41, "58": 20, "98": 11, "3": 160, "157": 6, "8": 99, "17": 48, "50": 23, "11": 78, "107": 10, "15": 54, "84": 13, "59": 20, "38": 26, "134": 7, "133": 7, "82": 13, "18": 46, "111": 10, "2": 168, "64": 19, "124": 7, "14": 56, "153": 6, "35": 28, "159": 6, "56": 21, "51": 23, "155": 6, "131": 7, "29": 34, "68": 17, "23": 39, "4": 154, "6": 112, "40": 25, "106": 10, "27": 36, "45": 24, "63": 19, "73": 16, "156": 6, "137": 7, "158": 6, "126": 7, "104": 10, "117": 9, "99": 11, "55": 22, "36": 27, "34": 29, "149": 6, "67": 18, "19": 45, "66": 18, "53": 23, "60": 20, "10": 85, "71": 16, "136": 7, "61": 19, "86": 13, "102": 11, "87": 13, "13": 67, "42": 25, "26": 37, "22": 40, "108": 10, "151": 6, "140": 7, "85": 13, "46": 24, "16": 51, "89": 13, "123": 8, "103": 11, "168": 5, "138": 7, "31": 33, "30": 34, "54": 23, "88": 13, "83": 13, "125": 7, "72": 16, "65": 19, "166": 5, "80": 13, "52": 23, "128": 7, "25": 38, "169": 5, "75": 15, "116": 9, "37": 26, "78": 14, "39": 26, "48": 24, "47": 24, "121": 8, "132": 7, "12": 76, "115": 9, "93": 12, "28": 36, "141": 7, "79": 14, "74": 15, "94": 12, "32": 32, "76": 14, "62": 19, "101": 11, "69": 17, "91": 12, "95": 12, "160": 5, "139": 7, "122": 8, "150": 6, "135": 7, "97": 11, "105": 10, "129": 7, "96": 11, "130": 7, "70": 16, "118": 9, "167": 5, "77": 14, "44": 24, "49": 24, "170": 5, "119": 9, "172": 5, "112": 9, "110": 10, "162": 5, "164": 5, "100": 11, "165": 5, "142": 7, "161": 5, "152": 6, "147": 6, "148": 6, "120": 8, "81": 13, "43": 25, "92": 12, "127": 7, "173": 5, "143": 7, "163": 5, "90": 12, "109": 10, "144": 7, "145": 7, "146": 7, "154": 6, "114": 9 }, "topic_mapper": [ [ -1, -1, -1 ], [ 0, 0, 24 ], [ 1, 1, 123 ], [ 2, 2, 53 ], [ 3, 3, 31 ], [ 4, 4, 93 ], [ 5, 5, 77 ], [ 6, 6, 172 ], [ 7, 7, 148 ], [ 8, 8, 22 ], [ 9, 9, 142 ], [ 10, 10, 46 ], [ 11, 11, 20 ], [ 12, 12, 85 ], [ 13, 13, 11 ], [ 14, 14, 113 ], [ 15, 15, 120 ], [ 16, 16, 152 ], [ 17, 17, 18 ], [ 18, 18, 15 ], [ 19, 19, 62 ], [ 20, 20, 168 ], [ 21, 21, 81 ], [ 22, 22, 66 ], [ 23, 23, 2 ], [ 24, 24, 44 ], [ 25, 25, 161 ], [ 26, 26, 147 ], [ 27, 27, 38 ], [ 28, 28, 97 ], [ 29, 29, 27 ], [ 30, 30, 129 ], [ 31, 31, 141 ], [ 32, 32, 151 ], [ 33, 33, 137 ], [ 34, 34, 131 ], [ 35, 35, 165 ], [ 36, 36, 39 ], [ 37, 37, 58 ], [ 38, 38, 67 ], [ 39, 39, 40 ], [ 40, 40, 116 ], [ 41, 41, 3 ], [ 42, 42, 36 ], [ 43, 43, 119 ], [ 44, 44, 64 ], [ 45, 45, 96 ], [ 46, 46, 65 ], [ 47, 47, 9 ], [ 48, 48, 7 ], [ 49, 49, 41 ], [ 50, 50, 63 ], [ 51, 51, 125 ], [ 52, 52, 12 ], [ 53, 53, 37 ], [ 54, 54, 35 ], [ 55, 55, 153 ], [ 56, 56, 114 ], [ 57, 57, 155 ], [ 58, 58, 70 ], [ 59, 59, 49 ], [ 60, 60, 103 ], [ 61, 61, 17 ], [ 62, 62, 127 ], [ 63, 63, 156 ], [ 64, 64, 8 ], [ 65, 65, 99 ], [ 66, 66, 126 ], [ 67, 67, 5 ], [ 68, 68, 79 ], [ 69, 69, 138 ], [ 70, 70, 102 ], [ 71, 71, 149 ], [ 72, 72, 135 ], [ 73, 73, 52 ], [ 74, 74, 139 ], [ 75, 75, 50 ], [ 76, 76, 124 ], [ 77, 77, 61 ], [ 78, 78, 19 ], [ 79, 79, 29 ], [ 80, 80, 13 ], [ 81, 81, 133 ], [ 82, 82, 21 ], [ 83, 83, 68 ], [ 84, 84, 112 ], [ 85, 85, 4 ], [ 86, 86, 117 ], [ 87, 87, 28 ], [ 88, 88, 160 ], [ 89, 89, 106 ], [ 90, 90, 56 ], [ 91, 91, 80 ], [ 92, 92, 78 ], [ 93, 93, 16 ], [ 94, 94, 166 ], [ 95, 95, 128 ], [ 96, 96, 170 ], [ 97, 97, 140 ], [ 98, 98, 60 ], [ 99, 99, 42 ], [ 100, 100, 134 ], [ 101, 101, 105 ], [ 102, 102, 54 ], [ 103, 103, 6 ], [ 104, 104, 88 ], [ 105, 105, 111 ], [ 106, 106, 108 ], [ 107, 107, 110 ], [ 108, 108, 74 ], [ 109, 109, 1 ], [ 110, 110, 32 ], [ 111, 111, 171 ], [ 112, 112, 92 ], [ 113, 113, 87 ], [ 114, 114, 130 ], [ 115, 115, 57 ], [ 116, 116, 109 ], [ 117, 117, 146 ], [ 118, 118, 136 ], [ 119, 119, 51 ], [ 120, 120, 143 ], [ 121, 121, 115 ], [ 122, 122, 43 ], [ 123, 123, 145 ], [ 124, 124, 72 ], [ 125, 125, 162 ], [ 126, 126, 23 ], [ 127, 127, 55 ], [ 128, 128, 167 ], [ 129, 129, 14 ], [ 130, 130, 144 ], [ 131, 131, 169 ], [ 132, 132, 0 ], [ 133, 133, 101 ], [ 134, 134, 89 ], [ 135, 135, 164 ], [ 136, 136, 122 ], [ 137, 137, 86 ], [ 138, 138, 150 ], [ 139, 139, 76 ], [ 140, 140, 107 ], [ 141, 141, 84 ], [ 142, 142, 69 ], [ 143, 143, 45 ], [ 144, 144, 163 ], [ 145, 145, 91 ], [ 146, 146, 83 ], [ 147, 147, 34 ], [ 148, 148, 94 ], [ 149, 149, 25 ], [ 150, 150, 71 ], [ 151, 151, 48 ], [ 152, 152, 75 ], [ 153, 153, 121 ], [ 154, 154, 173 ], [ 155, 155, 132 ], [ 156, 156, 30 ], [ 157, 157, 100 ], [ 158, 158, 118 ], [ 159, 159, 159 ], [ 160, 160, 98 ], [ 161, 161, 10 ], [ 162, 162, 104 ], [ 163, 163, 26 ], [ 164, 164, 90 ], [ 165, 165, 157 ], [ 166, 166, 158 ], [ 167, 167, 82 ], [ 168, 168, 47 ], [ 169, 169, 154 ], [ 170, 170, 33 ], [ 171, 171, 73 ], [ 172, 172, 95 ], [ 173, 173, 59 ] ], "topic_labels": { "-1": "-1_Immunotherapy and Tumor Microenvironment___", "0": "0_Cancer Survival and Healthcare Access___", "1": "1_\nChimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies___", "2": "2_Glioblastoma research and treatment___", "3": "3_\"3D Organoid Culture in Cancer Research\"___", "4": "4_Kras G12C Inhibitors and Resistance___", "5": "5_\nAcute Myeloid Leukemia Treatment and Drug Screening___", "6": "6_Spatial imaging of tissue microenvironments___", "7": "7_Prostate cancer and AR degradation___", "8": "8_Parp Inhibition and DNA Damage Repair___", "9": "9_Pancreatic Ductal Adenocarcinoma (PDAC) Microenvironment___", "10": "10_Topoisomerase 1 Inhibitors Adc Development___", "11": "11_Hepatocellular Carcinoma Treatment Research___", "12": "12_EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer___", "13": "13_Glutamine Metabolism in Cervical Cancer___", "14": "14_\n\"Nanoparticle-based cancer treatment\"___", "15": "15_Bone metastasis in breast cancer___", "16": "16_Microbiome and Immunotherapy in Cancer___", "17": "17_Triple Negative Breast Cancer (TNBC)___", "18": "18_\nOral Squamous Cell Carcinoma (OSCC) Research___", "19": "19_Melanoma therapy and Braf inhibitors___", "20": "20_Immunomodulation of Glioblastoma with Sting Agonism___", "21": "21_\n\"Anticancer mechanisms of natural compounds\"___", "22": "22_Renal Cell Carcinoma Subtypes___", "23": "23_\n\"Liquid Biopsy Using Urine and Plasma Samples\"___", "24": "24_Award ceremony speech draft___", "25": "25_\nTCR-engineered therapy for cancer treatment___", "26": "26_T-cell engagers for cancer treatment___", "27": "27_Colorectal cancer research___", "28": "28_Obesity and breast cancer___", "29": "29_Ferroptosis in cancer treatment___", "30": "30_Trop2-targeted ADCs for cancer treatment___", "31": "31_Hippo pathway inhibitors___", "32": "32_Immunotherapy in mice___", "33": "33_\nClinical trials of immunotherapies___", "34": "34_Immunity checkpoint inhibitors and resistance___", "35": "35_Pancreatic cancer research___", "36": "36_Drug combination screening___", "37": "37_\nPancreatic Cancer Research___", "38": "38_Her2 expression in solid tumors___", "39": "39_Smoking-induced lung cancer research___", "40": "40_\n\"Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer\"___", "41": "41_Prostate cancer research and treatment___", "42": "42_Cyclin-dependent kinase 2 inhibition in cancer therapy___", "43": "43_\n\"Methylation Detection from Cell-Free DNA\"___", "44": "44_Medulloblastoma research and treatment___", "45": "45_Single-cell RNA sequencing and chromatin accessibility analysis___", "46": "46_\n\"MTA-PRMT5 Inhibitors for Cancer Treatment\"___", "47": "47_Anti-PD-1 therapy in NSCLC___", "48": "48_Immunomodulation with IL-18 and PD-1 antagonists___", "49": "49_RMS and Pax3-Foxo1 Fusion Protein Research___", "50": "50_\n\"Chromatin organization and gene regulation in breast cancer\"___", "51": "51_Multi-Cancer Early Detection Tests___", "52": "52_\nMitochondrial dysfunction in cancer___", "53": "53_Cholangiocarcinoma research and treatments___", "54": "54_Immune cell analysis with cytof___", "55": "55_\n\"Circulating Tumor DNA Monitoring in Cancer Treatment\"___", "56": "56_Cellular thermal shift assay (CTSA) for target engagement___", "57": "57_\"FFPE Library Prep Methods\"___", "58": "58_\n\"Lung Cancer Classification and Targeting\"___", "59": "59_Immunotherapy biomarkers in cancer patients___", "60": "60_Colorectal cancer genomics and mutations___", "61": "61_Epithelial-mesenchymal transition and plasticity in cancer___", "62": "62_Electric fields for cancer treatment___", "63": "63_Cancer-associated fibroblasts in tumor microenvironment___", "64": "64_\nProstate cancer research and diagnosis___", "65": "65_\nAcquired drug resistance and persister cells___", "66": "66_\n\"EAC and Barrett's Esophagus Research\"___", "67": "67_\n\"Lung Cancer Research\"___", "68": "68_\n\"Cachexia and Muscle Wasting in Cancer Patients\"___", "69": "69_Cloud-based data governance for cancer research___", "70": "70_Ewing Sarcoma Research___", "71": "71_\n\"Immunotherapy targeting Tregs\"___", "72": "72_\nNano-immunotherapy for cancer treatment___", "73": "73_\n\"Trial of T-1101 and T-1201 in Cancer Treatment\"___", "74": "74_Radiation and Immunity in Cancer Treatment___", "75": "75_Immunotherapy and Neoantigens___", "76": "76_Aging and immune system in cancer___", "77": "77_\nProgesterone and breast cancer___", "78": "78_\n\"Gut Microbiome in CRC Patients\"___", "79": "79_Hematopoiesis and Clonal Variants___", "80": "80_\n\"Kinase Inhibition and Targeting\"___", "81": "81_Paralog selective degraders for cancer therapy___", "82": "82_\n\"Immunotherapy for Melanoma\"___", "83": "83_Genome-scale measurements for tumor normal benchmark___", "84": "84_Immunotherapy for bladder cancer___", "85": "85_Hematopoietic Progenitor Kinase 1 Inhibition___", "86": "86_\nVariants of Uncertain Significance (VUS)___", "87": "87_\n\"Colorectal cancer detection\"___", "88": "88_Claudin18 Targeted Therapy___", "89": "89_\n\"AI-based tumor purity analysis\"___", "90": "90_Bispecific antibody development for cancer treatment___", "91": "91_\n\"Genomic Variant Detection\"___", "92": "92_Prostate cancer in African men___", "93": "93_\n\"Microsatellite Instability and WRN Helicase Inhibition\"___", "94": "94_Immunosuppression and antibody-enhancing drugs___", "95": "95_\n\"Immune Checkpoint Inhibitor Adverse Events\"___", "96": "96_Neuronal influence on cancer growth___", "97": "97_\"Uveal Melanoma and Selenoproteome Expression\"___", "98": "98_HBV and HCC Treatment Studies___", "99": "99_\nBtk Inhibitors and Resistance Mechanisms___", "100": "100_\n\"Tertiary Lymphoid Structures in Cancer Prognosis\"___", "101": "101_Extrachromosomal DNA in cancer research___", "102": "102_Smarca2/4 degraders for cancer treatment___", "103": "103_\n\"Epigenetic Regulators and Cancer Treatment\"___", "104": "104_Bispecific anti-egfr/cmet adc___", "105": "105_Transposable elements and cancer___", "106": "106_\n\"ER Degradation Therapy for Breast Cancer\"___", "107": "107_Macrophage-based therapies in cancer___", "108": "108_\n\"Genomic Alterations in NSCLC\"___", "109": "109_Bladder Cancer Diagnosis and Monitoring___", "110": "110_\n\"Genomic profiling for cancer diagnosis\"___", "111": "111_TCR Repertoire in Cancer Patients___", "112": "112_Kras Vaccine Development___", "113": "113_\n\"G-quadruplex Targeting Compound in Pancreatic Cancer Treatment\"___", "114": "114_\nClinical efficacy of dual Her2 inhibition in metastatic colorectal cancer (MCRC)___", "115": "115_Liquid biopsy for glioma monitoring___", "116": "116_\nMismatch repair and immune checkpoint inhibitors___", "117": "117_\n\"Immunomodulatory effects of mushroom consumption in prostate cancer.\"___", "118": "118_Nectin-4 targeted ADCs___", "119": "119_Single-cell gene expression technologies___", "120": "120_\nHead and neck cancer subtyping___", "121": "121_Cancer Vaccine Development___", "122": "122_Proteomic analysis of cancer tissues___", "123": "123_\n\"Lymphoma Prognostics and Treatment Strategies\"___", "124": "124_\n\"Chemotherapy Resistance Mechanisms in Colorectal Cancer\"___", "125": "125_Cancer-associated fibroblasts research___", "126": "126_\nCondensate-based drug discovery___", "127": "127_\n\"Metabolism and Cancer Treatment\"___", "128": "128_Stat3 degraders for cancer therapy___", "129": "129_Melanoma research and embryonic development___", "130": "130_\n\"Ovarian Cancer Biomarkers\"___", "131": "131_\nLncRNA and Promoter Regulation in Cancer___", "132": "132_Immunotherapy in cancer treatment___", "133": "133_\n\"Ferroptosis in Cancer Cells\"___", "134": "134_\n\"Cdk4 Inhibitors and Breast Cancer Resistance\"___", "135": "135_Radiation therapy and DNA damage response inhibitors___", "136": "136_Liquid biopsy for cancer diagnosis and treatment response.___", "137": "137_Brain Metastasis Survival Analysis___", "138": "138_\nMolecular Biomarkers in Breast Cancer___", "139": "139_\nP53 and RPL22 in Cancer___", "140": "140_Colorectal cancer research___", "141": "141_\n\"Tumor Suppression Mechanisms\"___", "142": "142_Radiation-induced salivary gland damage and regeneration___", "143": "143_\n\"Adenosine Signaling and Immunotherapy\"___", "144": "144_Sarcopenia and ICI in NSCLC___", "145": "145_Ethnic disparities in lymphoma survival___", "146": "146_Liquid biopsy for lung cancer screening___", "147": "147_\n\"KDM6A Loss in Urothelial Carcinomas\"___", "148": "148_Immuno-oncology screens with CRISPR and RNA-seq___", "149": "149_P53 Restoration Therapy___", "150": "150_Immunometabolic targeting in cancer immunotherapy___", "151": "151_\n\"Breast cancer recurrence and gene regulation\"___", "152": "152_Head and neck squamous cell carcinoma (HNSCC) research___", "153": "153_\n\"HCC Immune Cells Study\"___", "154": "154_\n\"Pd-L1 IHC Scoring Methods\"___", "155": "155_Ovarian Cancer Glycosylation and Metastasis___", "156": "156_\n\"Ubiquitin-Proteasome System in Cancer Treatment\"___", "157": "157_\nClinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma___", "158": "158_Immunotherapy in Non-Small Cell Lung Cancer___", "159": "159_Anlotinib + Chemo for Advanced Escc Treatment___", "160": "160_\n\"Myc Targeting Technologies\"___", "161": "161_Neuroblastoma Epigenetics Study___", "162": "162_\n\"Metastasis and Genetic Alterations\"___", "163": "163_T Cell Exhaustion and Stemness Programs___", "164": "164_\nProstate cancer research___", "165": "165_\n\"Lung Cancer Microenvironment Analysis\"___", "166": "166_\n\"Pi3k/Akt Inhibitors in Breast Cancer\"___", "167": "167_\n\"Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis\"___", "168": "168_Extracellular Vesicle Research in Ovarian Cancer___", "169": "169_Colorectal Cancer Secondary Malignancies in Young Adults___", "170": "170_Molecular Glues Targeting Cancer-Specific E3 Ligases___", "171": "171_Epigenetics and Cancer Research___", "172": "172_Immunogenic neoantigens and NMD inhibition in cancer immunotherapy___", "173": "173_Click Activated Prodrugs Against Cancer Platform___" }, "custom_labels": [ "Immunotherapy and Tumor Microenvironment", "Cancer Survival and Healthcare Access", "Chimeric Antigen Receptor T Cell Therapy for B-Cell Malignancies", "Glioblastoma research and treatment", "3D Organoid Culture in Cancer Research", "Kras G12C Inhibitors and Resistance", "Acute Myeloid Leukemia Treatment and Drug Screening", "Spatial imaging of tissue microenvironments", "Prostate cancer and AR degradation", "Parp Inhibition and DNA Damage Repair", "Pancreatic Ductal Adenocarcinoma Microenvironment", "Topoisomerase 1 Inhibitors Adc Development", "Hepatocellular Carcinoma Treatment Research", "EGFR-TKIs and Resistance Mechanisms in Non-Small Cell Lung Cancer", "Glutamine Metabolism in Cervical Cancer", "Nanoparticle-based cancer treatment", "Bone metastasis in breast cancer", "Microbiome and Immunotherapy in Cancer", "Triple Negative Breast Cancer ", "Oral Squamous Cell Carcinoma Research", "Melanoma therapy and Braf inhibitors", "Immunomodulation of Glioblastoma with Sting Agonism", "Anticancer mechanisms of natural compounds", "Renal Cell Carcinoma Subtypes", "Liquid Biopsy Using Urine and Plasma Samples", "Award ceremony speech draft", "TCR-engineered therapy for cancer treatment", "T-cell engagers for cancer treatment", "Colorectal cancer research", "Obesity and breast cancer", "Ferroptosis in cancer treatment", "Trop2-targeted ADCs for cancer treatment", "Hippo pathway inhibitors", "Immunotherapy in mice", "Clinical trials of immunotherapies", "Immunity checkpoint inhibitors and resistance", "Pancreatic cancer research", "Drug combination screening", "Pancreatic Cancer Research", "Her2 expression in solid tumors", "Smoking-induced lung cancer research", "Stk11 Loss Drives Anti-PD1 Resistance in Lung Cancer", "Prostate cancer research and treatment", "Cyclin-dependent kinase 2 inhibition in cancer therapy", "Methylation Detection from Cell-Free DNA", "Medulloblastoma research and treatment", "Single-cell RNA sequencing and chromatin accessibility analysis", "MTA-PRMT5 Inhibitors for Cancer Treatment", "Anti-PD-1 therapy in NSCLC", "Immunomodulation with IL-18 and PD-1 antagonists", "RMS and Pax3-Foxo1 Fusion Protein Research", "Chromatin organization and gene regulation in breast cancer", "Multi-Cancer Early Detection Tests", "Mitochondrial dysfunction in cancer", "Cholangiocarcinoma research and treatments", "Immune cell analysis with cytof", "Circulating Tumor DNA Monitoring in Cancer Treatment", "Cellular thermal shift assay for target engagement", "FFPE Library Prep Methods", "Lung Cancer Classification and Targeting", "Immunotherapy biomarkers in cancer patients", "Colorectal cancer genomics and mutations", "Epithelial-mesenchymal transition and plasticity in cancer", "Electric fields for cancer treatment", "Cancer-associated fibroblasts in tumor microenvironment", "Prostate cancer research and diagnosis", "Acquired drug resistance and persister cells", "EAC and Barrett's Esophagus Research", "Lung Cancer Research", "Cachexia and Muscle Wasting in Cancer Patients", "Cloud-based data governance for cancer research", "Ewing Sarcoma Research", "Immunotherapy targeting Tregs", "Nano-immunotherapy for cancer treatment", "Trial of T-1101 and T-1201 in Cancer Treatment", "Radiation and Immunity in Cancer Treatment", "Immunotherapy and Neoantigens", "Aging and immune system in cancer", "Progesterone and breast cancer", "Gut Microbiome in CRC Patients", "Hematopoiesis and Clonal Variants", "Kinase Inhibition and Targeting", "Paralog selective degraders for cancer therapy", "Immunotherapy for Melanoma", "Genome-scale measurements for tumor normal benchmark", "Immunotherapy for bladder cancer", "Hematopoietic Progenitor Kinase 1 Inhibition", "Variants of Uncertain Significance ", "Colorectal cancer detection", "Claudin18 Targeted Therapy", "AI-based tumor purity analysis", "Bispecific antibody development for cancer treatment", "Genomic Variant Detection", "Prostate cancer in African men", "Microsatellite Instability and WRN Helicase Inhibition", "Immunosuppression and antibody-enhancing drugs", "Immune Checkpoint Inhibitor Adverse Events", "Neuronal influence on cancer growth", "Uveal Melanoma and Selenoproteome Expression", "HBV and HCC Treatment Studies", "Btk Inhibitors and Resistance Mechanisms", "Tertiary Lymphoid Structures in Cancer Prognosis", "Extrachromosomal DNA in cancer research", "Smarca2/4 degraders for cancer treatment", "Epigenetic Regulators and Cancer Treatment", "Bispecific anti-egfr/cmet adc", "Transposable elements and cancer", "ER Degradation Therapy for Breast Cancer", "Macrophage-based therapies in cancer", "Genomic Alterations in NSCLC", "Bladder Cancer Diagnosis and Monitoring", "Genomic profiling for cancer diagnosis", "TCR Repertoire in Cancer Patients", "Kras Vaccine Development", "G-quadruplex Targeting Compound in Pancreatic Cancer Treatment", "Clinical efficacy of dual Her2 inhibition in metastatic colorectal cancer ", "Liquid biopsy for glioma monitoring", "Mismatch repair and immune checkpoint inhibitors", "Immunomodulatory effects of mushroom consumption in prostate cancer.", "Nectin-4 targeted ADCs", "Single-cell gene expression technologies", "Head and neck cancer subtyping", "Cancer Vaccine Development", "Proteomic analysis of cancer tissues", "Lymphoma Prognostics and Treatment Strategies", "Chemotherapy Resistance Mechanisms in Colorectal Cancer", "Cancer-associated fibroblasts research", "Condensate-based drug discovery", "Metabolism and Cancer Treatment", "Stat3 degraders for cancer therapy", "Melanoma research and embryonic development", "Ovarian Cancer Biomarkers", "LncRNA and Promoter Regulation in Cancer", "Immunotherapy in cancer treatment", "Ferroptosis in Cancer Cells", "Cdk4 Inhibitors and Breast Cancer Resistance", "Radiation therapy and DNA damage response inhibitors", "Liquid biopsy for cancer diagnosis and treatment response.", "Brain Metastasis Survival Analysis", "Molecular Biomarkers in Breast Cancer", "P53 and RPL22 in Cancer", "Colorectal cancer research", "Tumor Suppression Mechanisms", "Radiation-induced salivary gland damage and regeneration", "Adenosine Signaling and Immunotherapy", "Sarcopenia and ICI in NSCLC", "Ethnic disparities in lymphoma survival", "Liquid biopsy for lung cancer screening", "KDM6A Loss in Urothelial Carcinomas", "Immuno-oncology screens with CRISPR and RNA-seq", "P53 Restoration Therapy", "Immunometabolic targeting in cancer immunotherapy", "Breast cancer recurrence and gene regulation", "Head and neck squamous cell carcinoma research", "HCC Immune Cells Study", "Pd-L1 IHC Scoring Methods", "Ovarian Cancer Glycosylation and Metastasis", "Ubiquitin-Proteasome System in Cancer Treatment", "Clinical Study of Hbw-3220 and Lp-284 in Aggressive Non-Hodgkin Lymphoma", "Immunotherapy in Non-Small Cell Lung Cancer", "Anlotinib + Chemo for Advanced Escc Treatment", "Myc Targeting Technologies", "Neuroblastoma Epigenetics Study", "Metastasis and Genetic Alterations", "T Cell Exhaustion and Stemness Programs", "Prostate cancer research", "Lung Cancer Microenvironment Analysis", "Pi3k/Akt Inhibitors in Breast Cancer", "Liquid Biopsy Analysis of Whole Blood for Cancer Diagnosis", "Extracellular Vesicle Research in Ovarian Cancer", "Colorectal Cancer Secondary Malignancies in Young Adults", "Molecular Glues Targeting Cancer-Specific E3 Ligases", "Epigenetics and Cancer Research", "Immunogenic neoantigens and NMD inhibition in cancer immunotherapy", "Click Activated Prodrugs Against Cancer Platform" ], "_outliers": 1, "topic_aspects": {} }